STLT - Spotlight Innovation Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0469
+0.0035 (+8.06%)
At close: 2:17PM EDT
Stock chart is not supported by your current browser
Previous Close0.0434
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume35,654
Market Cap1.617M
Beta-0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.5870
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.65
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Article Co-authored by Spotlight Innovation Research Collaborator Describes Small Molecule Drugs with In-vivo Efficacy Against Zika Virus Infection

    Spotlight Innovation Inc. (STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company research collaborator and Scientific Advisory Board member Professor Hengli Tang has co-authored an article, published in Cell Discovery on June 5, 2018, reporting potent antiviral activity and in-vivo efficacy of two small molecule drugs (emetine and cephaeline) against Zika virus (ZIKV) infection. “These small molecule compounds may prove to be viable drug candidates, and we are excited that Professor Tang and his collaborators continue to advance the field of anti-ZIKV therapies,” said Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development. Funding provided by Spotlight Innovation under a Sponsored Research Agreement with Florida State University is enabling Tang and his collaborators to expand on their discoveries and to accelerate the development of safe and effective drugs to treat patients infected with ZIKV.

  • GlobeNewswire2 months ago

    Spotlight Innovation Subsidiary Celtic Biotech Iowa Announces Results from Two Cohorts of Phase I Trial of Crotoxin for the Treatment of Cancer

    URBANDALE, IA, April 18, 2018-- Spotlight Innovation Inc., a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Celtic Biotech Iowa, Inc., reported ...

  • GlobeNewswire3 months ago

    Spotlight Innovation Subsidiary Celtic Biotech Iowa to Present Two Posters at 2018 American Association for Cancer Research (AACR) Annual Meeting

    URBANDALE, IA, March 28, 2018-- Spotlight Innovation Inc., a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Celtic Biotech Iowa, Inc., will ...

  • Marketwired9 months ago

    Spotlight Innovation Forms Corporate Partnership with University of Iowa Athletics to Promote New Chronic Pain Relief Product "Venodol"

    Spotlight Innovation Inc. today announced that it has formed a corporate partnership with University of Iowa Athletics that will provide ongoing radio and digital media visibility for the Venodol brand ...

  • PR Newswire10 months ago

    Spotlight Innovation Enters into Sponsored Research Agreement with Indiana University to Develop New Therapies for Spinal Muscular Atrophy

    URBANDALE, Iowa, Aug. 16, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that the Company has entered into a Sponsored Research Agreement with Indiana University to support research directed by Elliot Androphy, M.D., aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy (SMA). Dr. Androphy is a member of Spotlight Innovation's Scientific Advisory Board and a co-inventor of STL-182, the Company's lead product candidate for SMA. Geoffrey Laff, Ph.D., Spotlight Innovation's Senior Vice President of Business Development, commented, "Dr. Androphy is a prolific researcher and highly-respected thought leader.

  • PR Newswire10 months ago

    New Chronic Pain Relief Product "Venodol" Now Available for Pre-order at Venodol.com

    URBANDALE, Iowa, Aug. 7, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that its subsidiary Caretta Therapeutics' new over-the-counter chronic pain relief product, Venodol roll-on, is now available for pre-order in the U.S. at venodol.com. Venodol roll-on is a topical analgesic formulated to provide long-lasting relief from chronic pain associated with inflammation, including joint pain, tendinitis, arthritis (excluding osteoarthritis), and body aches. In the coming months Caretta Therapeutics plans to introduce additional Venodol product formats and to expand distribution to mass merchandise retailers through its Master Broker Agreement with a premier global distribution brokerage firm.

  • PR Newswire11 months ago

    Spotlight Innovation Subsidiary Caretta Therapeutics Engages Public Relations Firm TransMedia Group

    URBANDALE, Iowa, July 11, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that its subsidiary Caretta Therapeutics, LLC, has engaged TransMedia Group to provide public relations support for Venodol, a new over-the-counter, non-addictive alternative to opioid and steroidal analgesics that is tentatively scheduled to be available in the United States in summer 2017. "The TransMedia team's proven track record of generating consumer enthusiasm for products in the over-the-counter category makes them highly qualified to manage the product launch and to implement a product awareness strategy for Venodol," said John Krohn, Spotlight Innovation's President and Chief Executive Officer.

  • PR Newswirelast year

    Spotlight Innovation Enters into Sponsored Research Agreement to Develop New Therapies for Spinal Muscular Atrophy

    URBANDALE, Iowa, June 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that the Company has entered into a Sponsored Research Agreement with Brigham and Women's Hospital (BWH) to support research directed by Kevin Hodgetts, Ph.D., aimed at developing safe and effective drugs to treat patients with spinal muscular atrophy (SMA). Professor Hodgetts is a member of Spotlight Innovation's Scientific Advisory Board and a co-inventor of STL-182, the Company's lead product candidate for SMA.

  • PR Newswirelast year

    Spotlight Innovation Engages Investor Relations Firm PCG Advisory Group

    URBANDALE, Iowa, June 30, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that the Company has engaged PCG Advisory Group (PCG) to provide investor relations services in support of the Company and its drug development programs, and to strengthen its connection to the investment community. "We are pleased to partner with PCG, a pioneering integrated communications firm, to energize our investor relations activities," said John Krohn, Spotlight Innovation's President and Chief Executive Officer.

  • PR Newswirelast year

    Spotlight Innovation to Present Poster at the Cure SMA 2017 Annual SMA Conference

    URBANDALE, Iowa, June 22, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that the Company will participate in a family-friendly research poster session at the Cure SMA 2017 Annual SMA Conference, which the Company is supporting as a Silver Sponsor. On Friday, June 30, 2017, in the Fantasia Ballroom at Disney's Contemporary Resort in Orlando, FL, Dr. Geoffrey Laff will present a poster entitled STL-182, an Orally-available Small Molecule that Stabilizes SMN Protein. "We are proud to be a sponsor of this year's Cure SMA Annual SMA Conference and to present a poster designed to help families directly affected by SMA gain a better understanding of the disease," said Dr. Laff, Spotlight Innovation's Senior Vice President of Business Development.

  • PR Newswirelast year

    Spotlight Innovation Inc. Issues Statement About Recent Stock Trading Activity

    URBANDALE, Iowa, June 21, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (STLT) today announced that on June 15, 2017, it was made aware by OTC Markets of promotional activities surrounding the Company's common stock. According to the OTC Markets the activities were promotional newsletter emails encouraging investors to purchase the Company's common stock and this promotional activity coincided with higher than average trading volume and fluctuations in the Company's stock price.